GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won’t cover the treatments, especially at small and medium-sized firms.
The FDA’s approval of Eli Lilly’s Zepbound could signal more insurers paying for the use of such drugs. Demand is great so the costs could be big and push up premiums.
